Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?

Urologic Oncology: Seminars and Original Investigations

Volumn 35, Issue 1, 2017, Pages 34.e17-34.e25

  Brant, Aaron ^a   Kates, Max ^a   Chappidi, Meera R ^a   Patel, Hiten D ^a   Sopko, Nikolai A ^a   Netto, George J ^a   Baras, Alex S ^a   Hahn, Noah M ^a   Pierorazio, Phillip M ^a   Bivalacqua, Trinity J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Bladder cancer; Neoadjuvant chemotherapy; Radical cystectomy; TURBT

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

AGED; ARTICLE; BODY MASS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; POISSON DISTRIBUTION; PREVALENCE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; THERAPY EFFECT; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADULT; BLADDER TUMOR; DISEASE FREE SURVIVAL; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SMOOTH MUSCLE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR INVASION; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SMOOTH; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BURDEN; URINARY BLADDER NEOPLASMS;

EID: 84994831708     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2016.08.005     Document Type: Article

References (27)

1. [1] Advanced Bladder Cancer Meta-analysis Collaboration, Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet, 361, 2003, 1927.
2. [2] Advanced Bladder Cancer (ABC) Meta-analysis Collaboration, Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol, 48, 2005, 202.
3. [3] Advanced Bladder Cancer Overview Collaboration, Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev, 2005 CD005246.
4. [4] Clark, P.E., Agarwal, N., Biagioli, M.C., et al. Bladder cancer. J Natl Compr Canc Netw, 11, 2013, 446.
5. [5] Lavery, H.J., Stensland, K.D., Niegisch, G., et al. Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate. J Urol, 191, 2014, 898.
6. [6] Rosenblatt, R., Sherif, A., Rintala, E., et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol, 61, 2012, 1229.
7. [7] Sonpavde, G., Goldman, B.H., Speights, V.O., et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer, 115, 2009, 4104.
8. [8] Petrelli, F., Coinu, A., Cabiddu, M., et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol, 65, 2014, 350.
9. [9] Grossman, H.B., Natale, R.B., Tangen, C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med, 349, 2003, 859.
10. [10] Beukers, W., Meijer, T., Vissers, C.J., et al. Down-staging (
11. [11] Solsona, E., Iborra, I., Collado, A., et al. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol, 184, 2010, 475.
12. [12] Leibovici, D., Kassouf, W., Pisters, L.L., et al. Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology, 70, 2007, 473.
13. [13] Herr, H.W., Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol, 19, 2001, 89.
14. [14] Gandhi, N.M., Baras, A., Munari, E., et al. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urol Oncol, 33, 2015 204.e1.
15. [15] Zou, G., A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol, 159, 2004, 702.
16. [16] Kozuki, N., Katz, J., Christian, P., et al. Comparison of US Birth Weight References and the International Fetal and Newborn Growth Consortium for the 21st Century Standard. JAMA Pediatr, 169, 2015, e151438.
17. [17] Fedirko, V., Bradshaw, P.T., Figueiredo, J.C., et al. Urinary Metabolites of Prostanoids and Risk of Recurrent Colorectal Adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS). Cancer Prev Res (Phila), 8, 2015, 1061.
18. [18] Kirwa, K., Eliot, M.N., Wang, Y., et al. Residential proximity to major roadways and prevalent hypertension among postmenopausal women: results from the Women′s Health Initiative San Diego Cohort. J Am Heart Assoc, 3, 2014, e000727.
19. [19] Zargar, H., Espiritu, P.N., Fairey, A.S., et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol, 67, 2015, 241.
20. [20] Splinter, T.A., Scher, H.I., Denis, L., et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer—Genitourinary Group. J Urol, 147, 1992, 606.
21. [21] Nielsen, M.E., Bastian, P.J., Palapattu, G.S., et al. Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection. Urology, 70, 2007, 1091.
22. [22] Tollefson, M.K., Boorjian, S.A., Farmer, S.A., et al. Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease. World J Urol, 30, 2012, 795.
23. [23] Shariat, S.F., Palapattu, G.S., Karakiewicz, P.I., et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol, 51, 2007, 137.
24. [24] Volkmer, B.G., Kuefer, R., Bartsch, G. Jr., et al. Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival. Cancer, 104, 2005, 2384.
25. [25] Plimack, E.R., Dunbrack, R.L., Brennan, T.A., et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol, 68, 2015 959–957.
26. [26] Groenendijk, F.H., de Jong, J., Fransen van de, Putte E.E., et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 69 (2015), 384–388.
27. [27] Baras, A.S., Gandhi, N., Munari, E., et al. Identification and validation of protein biomarkers of response to neoadjuvant platinum chemotherapy in muscle invasive urothelial carcinoma. PLoS One, 10, 2015, e0131245.